Si­mone Song's ORI Cap­i­tal clos­es $260M sec­ond fund af­ter CG On­col­o­gy suc­cess

Si­mone Song re­calls dis­cussing on­colyt­ic virus ther­a­pies with her fa­ther and son “un­der the moon­light, like a fam­i­ly sci­en­tif­ic sym­po­sium” in South­ern Cal­i­for­nia in 2014. Af­ter the in­ter­gen­er­a­tional dis­cus­sion, she post­ed to WeChat about the sub­ject and, through busi­ness con­nec­tions, was even­tu­al­ly led to Arthur Kuan.

Song, then a man­ag­ing di­rec­tor for Greater Chi­na health­care in­vest­ment bank­ing at Gold­man Sachs, would go on to launch her own health­care VC firm, ORI Cap­i­tal, a year lat­er. And in 2017, ORI in­vest­ed in the blad­der can­cer ther­a­py at CG On­col­o­gy, which Kuan stepped in­to as CEO af­ter pre­vi­ous man­age­ment ran in­to trou­bles with a clin­i­cal hold, loss of a CD­MO con­tract and cash re­serves that with­ered to the point of just six weeks of run­way, she said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER